COMMUNIQUÉS West-GlobeNewswire

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
29/06/2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics [...]
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
29/06/2026
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58 Recent studies advanced science of molecular diagnostic [...]
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
29/06/2026
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults with MDD Primary [...]
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
29/06/2026
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
29/06/2026
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery [...]
HealthLynked Launches AI-Powered Healthcare Communication Platform Featuring 24/7 Appointment Scheduling and Medical Office AI Agents
29/06/2026
NAPLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK ), a leader in healthcare technology, patient engagement, and care coordination, today announced the launch of its next- [...]
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
29/06/2026
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
29/06/2026
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim [...]
Novo Nordisk A/S - share repurchase programme
29/06/2026
Bagsværd, Denmark, 29 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
29/06/2026
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy [...]
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
29/06/2026
4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest [...]
Dyadic Expands IP Protection and Business Development Activities in Japan
29/06/2026
Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the [...]
Conavi Medical Receives $1.25 Million Milestone Payment Under Ontario Life Sciences Scale-Up Fund
29/06/2026
Company has received $1.75 million in total under the program, including a $1.25 million payment triggered by the Company’s U.S. FDA clearance, to support the commercial launch of its hybrid IVUS-OCT imaging system [...]
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
29/06/2026
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
29/06/2026
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
29/06/2026
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
29/06/2026
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – [...]
GuideAI Health Corp. to Begin Trading on Cboe Canada Under the Symbol "GDAI"
29/06/2026
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (" GuideAI " or the " Company ") (Cboe CA: GDAI) is pleased to report that the Company has received final approval to list its common shares (the "Shares") [...]
Zymeworks to Acquire Theravance Biopharma, Inc.
29/06/2026
Acquisition adds YUPELRI ® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma [...]

Pages